JetBlue to Elevate Customer Experience With Expanded Paisly Offerings
ZACKS· 2025-06-27 18:56
Key Takeaways Paisly adds Holland America, Cunard, Virgin Voyages, and Oceania Cruises to its platform. JetBlue Vacations is the first to access the expanded cruise inventory through Paisly's platform. Paisly's expanding cruise partner roster strengthens its end-to-end travel service strategy.JetBlue Airways Corporation (JBLU) seems to be gearing up to strengthen its position in the airline industry with the renovation of its products. To this end, JBLU’s wholly-owned travel subsidiary and a tech-enabled ...
Molson Coors Hurt By Fewer People Drinking Beer, Warns Analyst
Benzinga· 2025-06-27 18:55
Bank of America Securities analyst Bryan D. Spillane downgraded Molson Coors Beverage Company TAP from Buy to Neutral, lowering the price forecast from $65 to $50.In December, the analyst upgraded Molson Coors, expecting U.S. beer volumes to return to normal 2025 trends and the company’s market share to stabilize, which would help sustain margins and support a higher valuation through better cash flow visibility.However, that outlook hasn’t materialized, industry volumes continue to fall below historical le ...
Nike Q4 FY25: The Turnaround Narrative Begins Now?
Seeking Alpha· 2025-06-27 18:50
Group 1 - Nike, Inc. has experienced a challenging year, with its stock declining and investor confidence waning, leading to concerns about the brand's relevance [1] Group 2 - The analysis emphasizes the importance of business models, earnings performance, and competitive positioning in evaluating publicly traded companies [2] - The focus is on long-term growth in sectors such as AI, fintech, finance, and tech, indicating a broader investment strategy [2] - The analyst aims to provide clear and unbiased insights into companies' strengths and valuation to assist investors in forming their own opinions [2]
Why BlackBerry Stock Soared This Week
The Motley Fool· 2025-06-27 18:43
Shares of BlackBerry (BB -4.66%) jumped this week, up 9% as of 1:22 p.m. ET on Friday. The rise comes as the S&P 500 (^GSPC 0.09%) and Nasdaq-100 gained 3.6% and 4.4%, respectively.The company, which has reinvented itself as a software provider, released its Q1 2026 (ended May 31) financial results, beating consensus estimates for most metrics and setting rosy guidance.BlackBerry reports positive numbersBlackBerry reported better-than-expected Q1 2026 results earlier this week. The company's first-quarter e ...
Lotus Technology: Selling Cars At Cost And Hemorrhaging Cash
Seeking Alpha· 2025-06-27 18:43
Core Viewpoint - Lotus Technology Inc. (NASDAQ: LOT) is recommended as a Sell for long-term investors despite its storied brand [1] Company Analysis - The analysis begins coverage of Lotus Technology Inc. with a negative outlook for long-term investors [1] - The company has a recognized brand, but further scrutiny reveals potential weaknesses [1]
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts
Benzinga· 2025-06-27 18:39
Core Insights - Altimmune, Inc. released topline results from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease [1] Group 1: Trial Details - The Phase 2b trial included 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses, or placebo for 24 weeks [2] - Treatment discontinuation rates were low, with only 9% of participants prematurely discontinuing treatment [3] Group 2: Efficacy Results - In an intent-to-treat (ITT) analysis, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% for pemvidutide 1.2 mg, 52.1% for 1.8 mg, and 19.1% for placebo (p< 0.0001 for both doses) [3] - The effects on fibrosis improvement without worsening of MASH were 31.8% for pemvidutide 1.2 mg, 34.5% for 1.8 mg, compared to 25.9% for placebo, although these differences were not statistically significant [4] Group 3: Analyst Ratings - HC Wainwright reiterated a Buy rating for Altimmune with a price forecast of $12, believing the data supports advancing pemvidutide to Phase 3 and strengthens its case as a potential best-in-class therapy [5] - Conversely, William Blair maintained a Market Perform rating, citing "underwhelming" results and concerns about demonstrating significant fibrosis improvement at the 48-week mark [6] Group 4: Stock Performance - ALT stock is trading lower by 1.80% to $3.545 at last check [7]
Natural Gas, WTI Oil, Brent Oil Forecasts – Oil Traders Stay Cautious As OPEC+ Is Reportedly Ready To Boost Production
FX Empire· 2025-06-27 18:38
Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, publications, and personal analysis intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].
CAROTE LTD(2549.HK):MACRO RISKS ARE MANIFOLD AND HAVE INTENSIFIED
Ge Long Hui· 2025-06-27 18:37
Core Viewpoint - The company is facing challenges in achieving its 30% sales growth target for FY25E due to weaker-than-expected sales trends, particularly in online sales in the US and China, and rising import tariffs impacting gross profit margins [1][5][7] Sales Growth Outlook - Sales growth in 2Q25E is expected to be slow, with estimates indicating a mixture of 10% growth in the US and negative growth in China and Europe, influenced by a high base from previous years and changing consumer interests [2][4] - The company has not altered its guidance of 30%+ sales growth for FY25E, but revised forecasts now suggest a more conservative 14% growth, down from 23%, with expectations of single-digit growth in 1H25E and 20% growth in 2H25E [4][7] Market-Specific Insights - In the US market, sales growth is projected at 10%, primarily driven by offline expansion, while e-commerce sales may face sluggish growth due to industry factors [4] - The Chinese market shows weak demand for small appliances and cookware, with potential year-over-year declines in sales for Carote in 1H25E and FY25E [4] - The European market is not a major focus for the company, leading to potentially weaker-than-expected sales growth [4] Impact of Tariffs - Recent increases in US tariffs on steel- and aluminium-based products could significantly impact gross profit margins, with total tariffs on Carote's products potentially reaching 73.3% [5][6] - The company may pass on about 15% of the tariffs through supply chain adjustments but will still face a 35% burden, leading to a revised gross profit margin assumption of around 33% for the US market in FY25E [6] Financial Forecast Adjustments - The company has downgraded its rating to HOLD and cut the target price to HK$ 4.64, based on a 10x FY25E P/E, reflecting a 28% reduction in net profit forecasts for FY25E due to weaker demand and higher import tariffs [1][7]
Why EchoStar Stock Is Skyrocketing Today
The Motley Fool· 2025-06-27 18:34
EchoStar (SATS 13.28%) stock is surging higher in Friday's trading following some big financial news. The company's share price was up 12.8% as of 2 p.m. ET. Meanwhile, the S&P 500 was up 0.3%.EchoStar submitted a filing with the Securities and Exchange Commission (SEC) indicating that it is making over $500 million in debt-interest payments. The payments had been overdue, but the fact that they are now being dispersed to creditors should help stave off bankruptcy risks. EchoStar rockets higher as interest ...
ValOre Announces Termination of Amalgamation Agreement with South Atlantic
Globenewswire· 2025-06-27 18:33
Core Viewpoint - ValOre Metals Corp. and its partners have mutually terminated the amalgamation agreement with South Atlantic Gold Inc. due to the failure of South Atlantic shareholders to approve the proposed amalgamation [1] Group 1: Company Overview - ValOre Metals Corp. is a Canadian company focused on deploying capital and expertise in projects that have seen substantial prior investment, possess high-value mineralization, and offer opportunities for value addition through exploration and innovation [2] Group 2: Amalgamation Details - The amalgamation agreement was intended for ValOre to indirectly acquire all issued and outstanding shares of South Atlantic [1] - The termination of the agreement was effective as of June 27, 2025, following the annual general and special meeting of South Atlantic [1]